Presented at the 2026 Heart Rhythm Society meeting in Chicago, the single-centre analysis compared 13,034 GLP-1 users with matched controls from more than 385,000 patients.
Researchers said GLP-1 users also had better survival, and lower atrial fibrillation risk persisted whether patients lost at least 10% of body weight, lost less, or gained weight.
Semaglutide showed the strongest association among drugs studied. The findings add to evidence of cardiovascular benefits beyond diabetes and obesity treatment, though larger, more diverse studies are still needed.
Could a genetic test soon tell you if a weight-loss drug is the best way to protect your heart?
If weight-loss drugs protect the heart without weight change, what hidden mechanisms are at play inside our bodies?
As benefits vanish upon stopping, are we creating a lifelong, costly dependency on these 'wonder drugs' for heart health?
Semaglutide and GLP-1 RAs Show Significant AF Risk Reduction and Cardiovascular Benefits Beyond Diabetes
Overview
Recent studies highlight that GLP-1 receptor agonists (GLP-1 RAs) significantly reduce atrial fibrillation (AF) risk in patients with obesity, both preventing new cases and lowering major AF-related events. These benefits arise mainly from direct effects on the heart, including reducing harmful epicardial fat and inflammation, improving heart cell function, and calming nerve activity that triggers arrhythmias. Notably, semaglutide stands out for its stronger impact due to its potent ability to shrink epicardial fat. These mechanisms work independently of weight loss and also enhance the success of AF treatments like catheter ablation, offering a promising new approach to managing AF beyond traditional methods.